Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.41 |
| ▸ | SIK1 | P57059 | 1/20 | 0.41 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491205 | 1.00 | SIK2 (0.41) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL23162267 | 0.86 | SIK1 (0.36) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL21593334 | 0.81 | SIK1 (0.42) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL23193791 | 0.80 | SIK2 (0.41) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL22747321 | 0.75 | SIK2 (0.55) | SIK2SIK1SIK3EGFRMEN1 | |
| SCHEMBL22491219 | 0.73 | SIK2 (0.40) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL29677035 | 0.73 | SIK2 (0.40) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL23193792 | 0.73 | SIK2 (0.37) | SIK2SIK1SIK3HTR2AHTR2C | |
| SCHEMBL22491255 | 0.70 | TP53 (0.36) | SIK2PARP1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL24169740 | 0.70 | SIK1 (0.37) | SIK2SIK1SIK3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2024-08-20 | — | — | US | disclosed |
| CN-111433200-B | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20220340581-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | SIK2 4122/4885SIK1 3852/4885SIK3 1967/4885 |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | SIK2 4122/4885SIK1 3852/4885SIK3 1967/4885 |
| US-20220340581-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | F12, F3, COL1A1 | SIK2 4122/4885SIK1 3852/4885SIK3 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.